Trilogy Capital’s Zoetis ZTS Stock Holding History

Trilogy Capital’s Portfolio ZTS Stock Details ZTS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-135	Closed	-$12K	–	586
2018 Q3	$12K	Hold	135	–	–	﹤0.01%	315
2018 Q2	$12K	Hold	135	–	–	﹤0.01%	286
2018 Q1	$11K	Buy	+135	New	+$10.6K	﹤0.01%	260

Other funds holding ZTS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Trilogy Capital's ZTS Position: Q4 2018 in Review

Trilogy Capital sold out of Zoetis (ZTS) in Q4 2018, closing a stake of 135 shares — an estimated $12K sold.

Trilogy Capital first reported a position in ZTS in Q1 2018 and held it in 3 quarters. The position peaked at $12K in Q3 2018. 1,028 funds tracked by Wall St. Rank hold ZTS as of Q4 2018.

Trilogy Capital reported no remaining Zoetis position as of Q4 2018 after selling out during the quarter.
Trilogy Capital sold 135 Zoetis shares in Q4 2018, an estimated $12K.
Trilogy Capital first reported a position in Zoetis in Q1 2018 and held it in 3 quarters.
Trilogy Capital's Zoetis position peaked at $12K in Q3 2018.
1,028 funds tracked by Wall St. Rank held Zoetis as of Q4 2018.

Based on Trilogy Capital's 13F filing for Q4 2018, filed 15 Jan 2019.